News

Bank7's Strategic Expansion through First American Mortgage Acquisition

Bank7's Strategic Expansion through First American Mortgage Acquisition

Bank7's Strategic Acquisition of First American Mortgage

Bank7 is thrilled to announce its recent acquisition of First American Mortgage, Inc., a prominent provider of residential mortgage lending services, further strengthening its mortgage division. This strategic move showcases Bank7's ongoing commitment to delivering top-notch financial solutions to its clients.

With a rich history spanning over 30 years, First American Mortgage has carved its niche in the mortgage industry. Initially established as a trusted leader in the field, it has built a reputation for providing customized lending solutions and outstanding customer service. By combining resources and expertise with First American Mortgage, Bank7 is poised to better serve the diverse needs of individuals, families, and businesses.

Jason Estes, President and CCO of Bank7, expressed excitement about this collaboration, stating, "We're thrilled to expand Bank7 by partnering with Dale and his team. Under Dale's guidance, First American Mortgage has excelled as an attentive and results-driven company. We look forward to working together to enhance service for customers across both firms."

Dale Bogle, President and Owner of First American Mortgage, added, "Our commitment to exceptional service and streamlined mortgage solutions remains steadfast. Joining forces with Bank7 allows us to elevate our offerings while keeping our dedication to clients and referral partners intact. This partnership opens a new chapter and presents exciting opportunities for growth and service enhancement."

The acquisition aligns seamlessly with Bank7's goal of growth and innovation as it seeks to solidify its status as a leading community-focused financial institution. Current customers of both Bank7 and First American Mortgage will enjoy the benefits of combined expertise, improved processes, and a broader network of lending professionals.

About Bank7

Headquartered in Oklahoma City, Bank7 operates twelve branches across Oklahoma, the Dallas/Fort Worth metropolitan area in Texas, and Kansas. The bank is dedicated to serving business owners and entrepreneurs with efficient, consistent, and well-structured loan and deposit products tailored to meet their financial demands. Bank7 aims to grow organically through strategic branch openings in key markets and actively pursues targeted acquisitions.

About First American Mortgage, Inc.

First American Mortgage has served local communities since 1993. Over the past 32 years, the company has facilitated more than $3 billion in funding, aiding approximately 18,000 families in achieving their dreams of home ownership. This impressive track record underscores First American Mortgage’s unwavering commitment to its clients.

Media Inquiries

For any media inquiries, contact Jason Estes, President and CCO, at 405-810-7270. The dedicated team is ready to provide further information regarding this transformative acquisition.

Frequently Asked Questions

What motivated Bank7's acquisition of First American Mortgage?

The acquisition was driven by Bank7's commitment to enhancing its mortgage division and providing comprehensive financial solutions to its customers.

How long has First American Mortgage been in operation?

First American Mortgage has been operating for over 30 years, establishing a solid reputation in residential mortgage lending.

What are the benefits for customers following this acquisition?

Customers will benefit from improved services, a larger network of lending professionals, and combined expertise from both organizations.

Who will be leading the merged operations?

Dale Bogle will continue to lead First American Mortgage as part of this partnership, working closely with Bank7's management to ensure a smooth transition.

What areas does Bank7 serve?

Bank7 operates in Oklahoma, the Dallas/Fort Worth area in Texas, and Kansas, focusing on supporting local business owners and entrepreneurs.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 36

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 26

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 35

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 37

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 31

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 34

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading

Top 5 Most Recently Viewed Articles

Bank of Canada Considers Interest Rate Cuts Amid Growth Concerns

Updated Category News Views 91

Bank of Canada Considers Possible Rate Cuts Recent discussions reported by the Financial Times reveal that Governor Tiff Macklem of the Bank of Canada has started exploring the possibility of increasing the pace at which interest rates could be cut. This potential shift highlights the Bank's response to growing concerns about the Canadian economy's current dynamics....

Continue Reading
Photonics Market Poised for Massive Growth by 2030

Updated Category News Views 151

Understanding the Photonics Market Growth The photonics industry is on an impressive trajectory, with projections indicating it will grow significantly over the coming years. Experts foresee the market expanding from approximately USD 1,093.96 billion to an astounding USD 1,481.80 billion by 2030, reflecting a compound annual growth rate (CAGR) of around 6.3%. This rapid...

Continue Reading
Brookfield Infrastructure Plans Redemption of Preferred Units

Updated Category News Views 154

Brookfield Infrastructure Announces Series 3 Redemption Plan BROOKFIELD, News - Brookfield Infrastructure Partners L.P. (TSX: BIP.UN; NYSE: BIP) has announced its intention to redeem all outstanding Cumulative Class A Preferred Limited Partnership Units, Series 3 (the “Series 3 Preferred Units”). This strategic decision aims to enhance their portfolio's financial...

Continue Reading
How a $1000 Investment in Enphase Energy Grew to $3200

Updated Category News Views 147

Transforming $1000 into $3200 with Enphase Energy Investing can be a journey filled with uncertainties, but the story of Enphase Energy (NASDAQ: ENPH) reveals a powerful lesson in the potential of financial growth. Over the past five years, Enphase Energy has impressively outperformed many market benchmarks, achieving a remarkable annualized return of 26.49%. At present,...

Continue Reading
Investors Should Pay Attention: Rocket Pharmaceuticals Lawsuit Update

Updated Category News Views 191

The Class Action Lawsuit Against Rocket Pharmaceuticals Recently, investors of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) have been advised to participate in a class action lawsuit for potential securities fraud. This lawsuit arises from significant concerns over the company's disclosure practices and the impact of leadership decisions on stock performance. If you are an...

Continue Reading